Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking.
about
Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuckAlpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulumStudy of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virusAntiviral effects of an iminosugar derivative on flavivirus infectionsImino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agentsA Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen SecretionNovel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity against FlavivirusesCurrent and future antiviral drug therapies of hepatitis B chronic infectionThe heterodimeric structure of glucosidase II is required for its activity, solubility, and localization in vivoSubstitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistanceα-Glucosidase inhibitors as potential broad based anti-viral agentsAnalysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus.The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans.The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infectionNovel approaches towards conquering hepatitis B virus infection.Iminosugars: Promising therapeutics for influenza infection.Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfection.Glycoproteins: rapid sequencing technology for N-linked and GPI anchor glycans.Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.Antiviral treatment of chronic hepatitis B virus (HBV) infectionsStructure-activity relationship of a new class of anti-hepatitis B virus agents.Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo.Evolving therapies for the treatment of chronic hepatitis B virus infection.Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs.Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment.Antiviral therapies and prospects for a cure of chronic hepatitis B.Emerging drugs for hepatitis B.Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus.Combination therapy for hepatitis BThe alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture.Intrinsic hepatocyte dedifferentiation is accompanied by upregulation of mesenchymal markers, protein sialylation and core alpha 1,6 linked fucosylationImino sugar glucosidase inhibitors as broadly active anti-filovirus agentsHepatitis B virus resistance to antiviral drugs: where are we going?Experimental models and therapeutic approaches for HBV.Treatment of delta hepatitis.The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120.
P2860
Q26828598-07E4FBD6-B053-4BC7-9AEC-4397219446F9Q27469618-293112B1-99AF-4363-9FC0-CA8D39631062Q27469853-C4E70B0D-E14E-4D1B-BA26-736DFD73F05DQ27472863-13EEA953-77DC-4987-945C-59CCAC4D5CC2Q27478192-6B68123F-BD32-4FBA-B177-E8335456D1F2Q27484471-3992AAB9-8642-4C03-B5B0-D428DC9824A1Q27488274-FFFCEF62-9666-4BC6-B907-769E1C6237BEQ28084820-2AB33408-AA5C-4BA6-A4F0-152D5431C4F8Q28142779-386F56F4-2ADD-4D4E-A5AA-8393982711A4Q28547647-329FB4FA-1717-4011-BC75-3FDAB806B7DEQ29036682-F478C5FE-CF5C-479C-98FC-1D49537547E9Q30671216-DB03E4DC-959F-464F-927C-282AD8AC4E5DQ33717397-F2667E5F-32A9-4E34-9C31-A2E616727EB2Q33756008-41ED9EC2-5560-4531-83EA-1BF04986AF1DQ33787525-CC389F29-ECCC-4C1C-B631-E3127B5AEFCCQ33787687-86E23A52-583F-44DD-BB81-DFF9FA90F5ECQ33795341-0D61BFFB-D266-4F6B-B928-700DD971B472Q33890105-7D0F45E3-6044-44DB-BDF8-E9FBC81F83CBQ33923384-DC452A82-00A2-49D2-81FF-E4F4325EEB15Q34045589-16732FA2-6489-4A23-B47A-3C79BEAFD29CQ34223779-7F6B8E48-EA0E-443F-948F-ED637DFDED86Q34251931-F4882704-DECD-4EF0-9526-B318375E1A03Q34478823-6FFA7A6F-BE55-42C4-9176-B28317D0EF05Q34519117-DB5C0730-8A0B-4BF1-91DB-9569E427F1BDQ34534466-20FD01F6-8D59-4F9E-A9DA-5DA9FEC35F2FQ34557737-2F28C775-BFE2-44CC-80A7-86AAAB909CC6Q34644755-83A11CE1-5319-4CD9-B83E-63873ACDD62AQ34693445-20D835B5-A2E3-46F8-9BA1-3B4FDA410650Q35075630-A37F784A-9A6D-4319-B376-C7A81DF579F5Q35245231-C73ABE23-E5D2-4240-8516-1B54FBAB8A13Q35359369-90C2E430-E33C-464A-A0E9-C18FCA60EF3FQ35548601-96B4E0DB-1CF6-4DEB-B506-A3A1CBE340DDQ35594472-C5C07155-5146-48CB-8E44-1DC9E1B1DE6CQ36890738-B4C0445C-FEAE-4E0D-9BE8-B272288904FBQ37027426-1EC1DA6B-E9AF-468E-B1D1-A3B5B6FFD88CQ37584342-AF32762B-DF8D-4515-ADA1-2ED39BAA519DQ37825963-162C5A94-1E44-4715-BC6A-F5E019AE21A5Q38035173-0DEFDA14-6A07-4775-92AA-F29AB0149A82Q38102778-EAB811B8-ACE5-450F-8719-88183499DCA9Q38302147-3DF5BA42-D586-4785-8159-18F8E273AE7C
P2860
Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Treatment of chronic hepadnavi ...... otein folding and trafficking.
@en
Treatment of chronic hepadnavi ...... otein folding and trafficking.
@nl
type
label
Treatment of chronic hepadnavi ...... otein folding and trafficking.
@en
Treatment of chronic hepadnavi ...... otein folding and trafficking.
@nl
prefLabel
Treatment of chronic hepadnavi ...... otein folding and trafficking.
@en
Treatment of chronic hepadnavi ...... otein folding and trafficking.
@nl
P2093
P2860
P356
P1433
P1476
Treatment of chronic hepadnavi ...... otein folding and trafficking.
@en
P2093
Blumberg BS
P2860
P2888
P304
P356
10.1038/NM0598-610
P407
P577
1998-05-01T00:00:00Z